The clinical benefit of a new genomic instrument, the 70-gene signature\ud
for breast cancer patients, is being evaluated in a randomised clinical\ud
trial. The early, controlled implementation process is supported by a\ud
Constructive Technology Assessment to help decision-making in an\ud
uncertain time of developmen